NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Forecast, Price & News

$1.19

+0.01 (+0.85%)

(As of 05/31/2023 ET)

Compare

Today's Range: $1.17
▼
$1.21
50-Day Range: $0.95
▼
$1.55
52-Week Range: $0.50
▼
$6.38

Volume: 6,238 shs
Average Volume: 19,243 shs
Market Capitalization: $16.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Kazia Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 68.1% Upside
$2.00 Price Target
Short Interest: Healthy
0.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.11) to ($0.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

658th out of 1,006 stocks

Pharmaceutical Preparations Industry

331st out of 492 stocks

3.3

Analyst's Opinion

Consensus Rating
Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, Kazia Therapeutics has a forecasted upside of 68.1% from its current price of $1.19.
Amount of Analyst Coverage
Kazia Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.97% of the outstanding shares of Kazia Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Kazia Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kazia Therapeutics has recently decreased by 24.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kazia Therapeutics does not currently pay a dividend.
Dividend Growth
Kazia Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KZIA.

1.8

News and Social Media Coverage

News Sentiment
Kazia Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kazia Therapeutics this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Kazia Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.47% of the stock of Kazia Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kazia Therapeutics are expected to grow in the coming year, from ($1.11) to ($0.62) per share.
Price to Book Value per Share Ratio
Kazia Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kazia Therapeutics (NASDAQ:KZIA) Stock

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Stock News Headlines

May 27, 2023 | americanbankingnews.com

Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Decline in Short Interest

May 25, 2023 | finance.yahoo.com

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 1, 2023 | proactiveinvestors.com

Kazia Therapeutics appoints Dr John Friend as new CEO

April 15, 2023 | americanbankingnews.com

Analysts Set Expectations for Kazia Therapeutics Limited's FY2026 Earnings (NASDAQ:KZIA)

April 14, 2023 | finance.yahoo.com

KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

April 14, 2023 | americanbankingnews.com

Analysts Offer Predictions for Kazia Therapeutics Limited's FY2024 Earnings (NASDAQ:KZIA)

April 13, 2023 | americanbankingnews.com

Kazia Therapeutics (NASDAQ:KZIA) Stock Rating Upgraded by HC Wainwright

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

April 4, 2023 | finance.yahoo.com

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

April 3, 2023 | proactiveinvestors.com

Kazia Therapeutics to present new pipeline molecule data at AACR 2023

April 2, 2023 | americanbankingnews.com

Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short Interest

March 6, 2023 | proactiveinvestors.com

Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers

February 27, 2023 | proactiveinvestors.com

Kazia Therapeutics raises A$7 million to fund R&D pipeline

February 22, 2023 | seekingalpha.com

KZIA Kazia Therapeutics Limited

February 18, 2023 | benzinga.com

Kazia Therapeutics Stock (NASDAQ:KZIA), Quotes and News Summary

February 13, 2023 | finance.yahoo.com

Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

February 5, 2023 | msn.com

After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023

January 25, 2023 | finance.yahoo.com

Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares

January 18, 2023 | finance.yahoo.com

Kazia Therapeutics CEO talks $4.5 million capital raise

January 16, 2023 | msn.com

Kazia raises A$4.5M to progress R&D programs

January 16, 2023 | finance.yahoo.com

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

December 20, 2022 | proactiveinvestors.com.au

Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research

December 19, 2022 | finance.yahoo.com

Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies

December 15, 2022 | finance.yahoo.com

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

December 12, 2022 | finance.yahoo.com

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

December 7, 2022 | proactiveinvestors.com

Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Company Calendar

Today: 5/31/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KZIA
CUSIP: N/A
CIK: 1075880
Web: www.kaziatherapeutics.com
Phone: (129) 472-4101
Fax: 61-2-9476-0388
Employees: 2,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.00
High Stock Price Forecast: $2.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +68.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.06
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $11.35 million
Price / Sales: 1.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 1.23

Miscellaneous

Outstanding Shares: 13,880,000
Free Float: 13,737,000
Market Cap: $16.52 million
Optionable: Not Optionable
Beta: 2.20

Key Executives

John E. Friend
Chief Executive Officer

Karen R. Krumeich
Chief Financial Officer

Anna Sandham
Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KZIA Stock - Frequently Asked Questions

Should I buy or sell Kazia Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KZIA shares.
View KZIA analyst ratings or view top-rated stocks.
What is Kazia Therapeutics' stock price forecast for 2023?: 2 analysts have issued 12-month price objectives for Kazia Therapeutics' shares. Their KZIA share price forecasts range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 68.1% from the stock's current price.
View analysts price targets for KZIA or view top-rated stocks among Wall Street analysts.
How have KZIA shares performed in 2023?: Kazia Therapeutics' stock was trading at $0.6149 on January 1st, 2023. Since then, KZIA shares have increased by 93.5% and is now trading at $1.19.
View the best growth stocks for 2023 here.
Are investors shorting Kazia Therapeutics?: Kazia Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 134,300 shares, a decline of 24.4% from the April 30th total of 177,700 shares. Based on an average daily volume of 44,200 shares, the short-interest ratio is presently 3.0 days.
View Kazia Therapeutics' Short Interest.
What other stocks do shareholders of Kazia Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Translate Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA).
What is Kazia Therapeutics' stock symbol?: Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?: Kazia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.49%).
How do I buy shares of Kazia Therapeutics?: Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kazia Therapeutics' stock price today?: One share of KZIA stock can currently be purchased for approximately $1.19.
How much money does Kazia Therapeutics make?: Kazia Therapeutics (NASDAQ:KZIA) has a market capitalization of $16.52 million and generates $11.35 million in revenue each year.
How many employees does Kazia Therapeutics have?: The company employs 2,021 workers across the globe.
How can I contact Kazia Therapeutics?: Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The official website for the company is www.kaziatherapeutics.com. The company can be reached via phone at (129) 472-4101, via email at investment.consultant@novogen.com, or via fax at 61-2-9476-0388.

This page (NASDAQ:KZIA) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial